ArticleBMC rheumatology2025
The impact of intensive management on pain intensity in patients with rheumatoid arthritis and psoriatic arthritis: secondary analysis of three clinical trials.
Article in BMC rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Baseline pain, fatigue, and sleep quality predict 12-week pain improvement in inflammatory arthritis: retrospective real-world analysis of a digital health application cohort.Rheumatology international · 2026Article
- The impact of intensive management on pain intensity in patients with rheumatoid arthritis and psoriatic arthritis: secondary analysis of three clinical trials.BMC rheumatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundUnderstanding the impact of intensive treatment on pain in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) is crucial to informing the application of evidence-based arthritis pain care. The impact of intensive treatment on inflammatory arthritis pain has received relatively limited attention. We addressed this through a detailed secondary analysis of three trials evaluating varying intensities of disease-modifying anti-rheumatic drug treatment. We considered a range of pain outcomes of clinical relevance to patients, including the achievement of mild endpoint pain scores and clinically-meaningful pain reductions.
methodsThe trials comprised MIPA in PsA, CARDERA in early RA, and TITRATE in established RA. Pain was measured using a 100-mm pain intensity visual analogue scale (VAS). The impact of intensive treatment on (a) patients achieving "mild" endpoint pain intensity scores (of ≤ 34), b) mean changes in pain intensity scores, and (c) patients achieving ≥ 30% reductions in pain intensity scores was evaluated using t-tests, chi-squared tests, and regression models (with the latter adjusting for relevant potential confounding variables).
resultsFrom MIPA, CARDERA, and TITRATE 128, 379, and 258 patients had endpoint outcome data available and were included in this secondary analysis. In all trials, significantly more patients achieved mild endpoint pain intensity scores with intensive vs. control treatment (MIPA 70% vs. 42%, P = 0.003; CARDERA 71% vs. 56%, P = 0.011; TITRATE 67% vs. 50%, P = 0.008). In the two trials employing the most intensive management strategies (CARDERA; TITRATE) overall reductions in pain scores were significantly greater (6.6 to 6.8 units in adjusted linear regression models), and significantly more achieved ≥ 30% reductions in pain with intensive vs. control treatment (adjusted logistic regression models: CARDERA odds ratio [OR] 1.9, P = 0.009; TITRATE OR 2.2, P = 0.002).
conclusionsIntensive treatment is an important component of improving pain in patients with active RA and PsA. Our findings support EULAR guidance that optimising disease activity is crucial for pain control. As approximately one third of patients receiving active treatment had moderate/high endpoint pain intensity levels across trials, additional pain management strategies that complement intensive treatment are needed.
trial registrationCurrent Controlled Trials CARDERA ISRCTN32484878 (25/10/2000), MIPA ISRCTN54376151 (04/02/2002), and TITRATE ISRCTN70160382 (16/1/2014).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.